Medpace, Inc. Managing Director, Dr. Tufail Syed, to Present at the Clinical Trials Congress, India 2010 on January 21, 2010

CINCINNATI, OH--(Marketwire - January 07, 2010) -

Medpace, Inc., a leading global full-service clinical research organization today announced that Dr. Tufail Syed, Managing Director, Medpace India will speak at the upcoming Clinical Trials Congress in Mumbai, January 20th-22th. Industry professionals will discuss the practical and operational realities of conducting clinical trials in India. Dr. Syed’s topic will address sourcing the right partners to successfully penetrate the Indian market for successful drug development.

Tufail Syed, MD, is the Medpace General Manager, and country head, for Medpace India, located in Mumbai. Dr. Syed is an endocrinologist, trained from State University of New York, with significant experience and medical knowledge in medical affairs and clinical studies. Dr. Syed has pioneered several initiatives for the development of the clinical research in India. He is a frequent speaker on issues related to clinical research in India and Asia Pacific, and is recognized as subject matter expert in clinical development. In 2006, he founded the Clinical Research Forum (http://www.clinicalresearchforum.com) which is widely recognized as the best online community of clinical research professionals worldwide. Prior to joining Medpace in 2006, Dr. Syed worked as Medical Advisor for Eli Lilly and Company, where he oversaw medical affairs and clinical operations for all diabetes, metabolism, and oncology clinical trials. Dr. Syed designed clinical studies and has written protocols, study reports, and manuscripts.

ABOUT MEDPACE

Medpace is a leading global full-service clinical research organization providing Phase I-IV core development services for drug, biologic, and device programs. With medical and regulatory expertise in multiple therapeutic specialties, Medpace has assembled the industry’s most experienced and therapeutically focused teams to execute at every level of the company’s operations, providing complete and seamless drug development services. In June 2009 Medpace was rated as the best CRO by U.S. Investigators in the 2009, CenterWatch Site Survey.

Medpace creates strategic partnerships with pharmaceutical and biotechnology companies to provide the most efficient and cost-effective path to drug development -- from program planning and execution to product approval.

With more than 1,000 employees and clinical trial experience in over 40 countries, Medpace has the global reach and capability to conduct studies and navigate regulatory requirements worldwide. In addition to Phase II-IV development services, Medpace provides Phase I / IIA clinical services from Medpace Clinical Pharmacology, central laboratory and therapeutically specialized testing from Medpace Reference Laboratories, complete bioanalytical services in all stages of drug development from Medpace Bioanalytical Laboratories, and centralized imaging core laboratory management and reading from Imagepace.

Visit the Medpace website at www.medpace.com